Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-ESIDRIX #2 vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine is extensively metabolized in the liver via hydrolysis and conjugation, with metabolites excreted in urine and feces. Hydrochlorothiazide is not metabolized extensively; it is primarily eliminated unchanged by the kidneys.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Reserpine: 96% bound to albumin; Hydrochlorothiazide: 40-68% bound to albumin.
~90%, primarily to albumin
Reserpine: 5-8 L/kg (extensive tissue binding, particularly to adrenergic neurons); Hydrochlorothiazide: 0.83-1.14 L/kg (distributes into extracellular fluid).
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Reserpine: 50-60% (oral, extensive first-pass metabolism); Hydrochlorothiazide: 65-75% (oral, with food decreasing absorption by 10-20%).
Oral: 50–60% (extensive first-pass metabolism)
Contraindicated if GFR < 30 m L/min. For GFR 30-59 m L/min, maximum dose is 1 tablet every other day due to hydrochlorothiazide accumulation.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: caution, consider reducing dose. Child-Pugh B: contraindicated due to risk of hepatic coma and reserpine-induced depression. Child-Pugh C: contraindicated.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not recommended for children. Safety and efficacy not established.
Not recommended for pediatric use; safety in children under 12 years not established.
Initiate with 0.5 tablet once daily due to increased sensitivity to reserpine (CNS depression) and hydrochlorothiazide (hypotension, electrolyte imbalance). Titrate slowly.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Reserpine may cause depression, and should be discontinued if symptoms occur; use with caution in patients with history of depression.,Hydrochlorothiazide may cause electrolyte imbalances (e.g., hypokalemia), dehydration, and increased serum uric acid and glucose.,May cause orthostatic hypotension, especially with alcohol or other antihypertensives.,Renal impairment: monitor renal function.,Hepatic impairment: use with caution as reserpine may precipitate hepatic encephalopathy.,Sulfonamide allergy: hydrochlorothiazide is a sulfonamide derivative; cross-sensitivity may occur.,May require dosage adjustment in renal impairment.,Avoid abrupt discontinuation of reserpine; taper gradually.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to reserpine, hydrochlorothiazide, or sulfonamides.,History of mental depression or suicidal tendencies.,Active peptic ulcer or ulcerative colitis.,Electroconvulsive therapy (ECT) within 7 days.,Anuria or severe renal impairment (e.g., creatinine clearance <30 m L/min).,Pheochromocytoma (reserpine may paradoxically increase blood pressure).
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
High-potassium foods (bananas, oranges, spinach) may increase risk of hyperkalemia if used with potassium-sparing diuretics; however, hydrochlorothiazide is potassium-wasting, so hypokalemia risk exists. Avoid excessive sodium intake (processed foods, salt) as it can reduce antihypertensive effect. Grapefruit juice may interact with reserpine; limit consumption.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of skeletal and cardiovascular anomalies. Second and third trimesters: Possible adverse effects including neonatal respiratory depression, bradycardia, hypothermia, and hypotonia. Esidrix (hydrochlorothiazide) is FDA Pregnancy Category B; however, thiazide diuretics may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances. Use only if clearly needed.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine is excreted into breast milk; M/P ratio not established. Potential for severe adverse effects in nursing infants including respiratory depression, bradycardia, and hypotonia. Hydrochlorothiazide is excreted in breast milk in low amounts (M/P ratio approximately 0.4-0.5), but may suppress lactation and cause electrolyte disturbances. Avoid breastfeeding during therapy.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Pregnancy can increase volume of distribution and renal clearance, potentially reducing drug concentrations. No specific dose adjustment studies for Serpasil-Esidrix #2; however, based on components: Hydrochlorothiazide may require increased dose due to enhanced clearance, but use lowest effective dose. Reserpine dosing should be minimized due to fetal risks. Avoid use in pregnancy if possible; alternative antihypertensives recommended.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Serpasil (reserpine) plus Esidrix (hydrochlorothiazide) #2 is a fixed-dose combination for hypertension. Reserpine depletes catecholamines: monitor for depression, nasal congestion, sedation, and bradycardia. Hydrochlorothiazide: check electrolytes, uric acid, glucose; avoid in anuria. Onset of reserpine action is slow (weeks) but prolonged (weeks after discontinuation). Combination may exacerbate gout and diabetes.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop suddenly as high blood pressure may worsen.,May cause drowsiness or dizziness; avoid driving or operating heavy machinery until effects are known.,Avoid alcohol as it can increase dizziness and drowsiness.,Report symptoms of depression, slow heart rate, severe nasal congestion, or unusual bleeding/bruising.,Use sun protection as hydrochlorothiazide increases sun sensitivity.,Monitor for signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, excessive thirst.,Inform all healthcare providers you are taking this medication, especially before surgery.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-ESIDRIX #2 vs ALDORIL 15, answered by our medical review team.
SERPASIL-ESIDRIX #2 is a Antihypertensive Combination that works by Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-ESIDRIX #2 and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-ESIDRIX #2 is: 1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-ESIDRIX #2 and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-ESIDRIX #2 is classified as Category C. Serpasil (reserpine) is classified as FDA Pregnancy Category C. Reserpine crosses the placenta. First trimester: Limited human data, but animal studies suggest increased risk of sk. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.